/ News / 24 Jul 2020 / Katie Hickmer
Aroa Biosurgery (Aroa), a soft tissue regeneration company, commences trading today on the Australian Securities Exchange (ASX). After raising $45 million from investors, the IPO (initial public
offering) values Aroa at A$225 million under the code ARX.
Founded in 2008, the company’s Endoform® soft tissue regeneration technology, derived from sheep forestomach, was developed to improve the rate and quality of healing in complex wounds
and soft tissue reconstruction.
New Zealand Growth Capital Partners (NZGCP) have co-invested in Aroa since 2008 via their Aspire NZ Seed Fund.
“The involvement of early investors, including Movac and NZGCP, provided a patient, supportive capital base. By being able to see Aroa’s future prospects during our development phase, this family of investors has enabled Aroa to mature to the point where we can now raise capital through the fully public market and move forward on our continued growth plans,” says Aroa Chief Executive, Brian Ward.
“Aroa Biosurgery, which currently has five FDA-approved products in the market which have been used in over four million procedures to date, is a great success story for New Zealand's innovative healthcare industry,” says NZGCP Investment Director, Marcus Henderson.
“The company has developed hugely innovative healthcare products with regulatory clearance in more than 37 countries and a deep patent portfolio. On the back of these achievements and strong revenue growth, we are delighted that Aroa has successfully listed on the ASX and is now poised to accelerate growth in the USA, Canada, Europe and Asia.”
Media contact: David Lewis 021 976 119
14 Jun 2021
Join NZGCP and AANZ for a series of Early Stage Investment workshops. 'Government Support' on 15…
14 Jun 2021
Join our team...
At NZGCP you’re not just an employee, you’re part of something bigger, and…